Evaluating ABUS requires an assessment of the HBV program, which I’ve posted about from time to time—see, for instance, #msg-154612542 and the thread it replies to. (#msg-151513575 has info on a now-defunct ABUS HBV compound.)
2% seems a little low for the presumed LNP royalty, assuming that ABUS continues to prevail in continuing litigation with MRNA.
Market Data 
Markets 
AI
